H-P: Analysts' Upgrades, Downgrades

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Amylin Pharmaceuticals (AMLN Quote) upgraded at Barclays to Overweight from Equal Weight. Price target lifted to $22 from $16. 2009 and 2010 EPS estimates set at -$1.25 and -$0.35, respectively.

Acuity Brands (AYI Quote) upgraded at Oppenheimer from Market Perform to Outperform. $40 price target. Valuation call, as the company should see traction in market share and improving execution.

Coca-Cola Enterprises (CCE Quote) rated new Hold at Citigroup. $23 price target. Company is more volatile, because of its high exposure to commodity prices.

Cephalon (CEPH Quote) target reduced at Goldman. Shares of CEPH now seen reaching $64. Trial failure of Cinquil hurts the company's revenue visibility. Buy rating.

Cephalon (CEPH Quote) upgraded at Jefferies from Hold to Buy. $63 price target. Stock is already pricing in negative news and there's upside potential for Treanda sales.

Ciena (CIEN Quote) target boosted at Citigroup. Shares of CIEN now seen reaching $18.50. Still believe the Nortel deal makes strategic sense. Buy rating.

Ciena (CIEN Quote) downgraded at Jefferies from Hold to Underperform. $12 price target. See several risks surrounding the Nortel acquisition.

Lexicon Pharmaceuticals (LXRX Quote) initiated at Thomas Weisel with and Overweight rating and $2.50 price target. 2009 and 2010 EPS estimates set at -$0.55 and -$0.54, respectively.

Prudential Financial (PRU Quote) upgraded at Wells from Market Perform to Outperform. Company is emerging from the financial crisis in a relatively strong position.

Reliance Steel (RS Quote) upgraded at UBS from Neutral to Buy. Company should see more M&A opportunities materialize. $50 price target.